Sei Investments CO Fate Therapeutics Inc Transaction History

Sei Investments CO

  • $74.7 Billion
  • Q3 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$1.65 - $3.94 $29,808 - $71,180
18,066 New
18,066 $67,000
Q3 2022

Nov 14, 2022
BUY
$21.04 - $36.06 $257,550 - $441,410
12,241 Added 23.14%
65,144 $1.46 Million
Q2 2022

Aug 15, 2022
BUY
$17.78 - $42.39 $940,615 - $2.24 Million
52,903 New
52,903 $1.31 Million
Q4 2021

Feb 14, 2022
SELL
$47.84 - $64.34 $283,308 - $381,021
-5,922 Closed
0 $0
Q3 2021

Nov 12, 2021
SELL
$59.27 - $95.73 $50,972 - $82,327
-860 Reduced 12.68%
5,922 $353,000
Q2 2021

Aug 06, 2021
SELL
$67.25 - $92.52 $823,879 - $1.13 Million
-12,251 Reduced 64.37%
6,782 $588,000
Q1 2021

May 12, 2021
BUY
$72.16 - $117.4 $45,460 - $73,962
630 Added 3.42%
19,033 $1.66 Million
Q4 2020

Feb 08, 2021
SELL
$38.09 - $100.95 $85,397 - $226,329
-2,242 Reduced 10.86%
18,403 $1.67 Million
Q3 2020

Nov 06, 2020
BUY
$30.41 - $40.5 $137,514 - $183,141
4,522 Added 28.05%
20,645 $823,000
Q2 2020

Aug 11, 2020
SELL
$20.21 - $35.23 $163,357 - $284,764
-8,083 Reduced 33.39%
16,123 $553,000
Q1 2020

May 14, 2020
BUY
$17.28 - $31.88 $418,279 - $771,687
24,206 New
24,206 $538,000
Q1 2019

May 15, 2019
SELL
$13.15 - $18.71 $57,334 - $81,575
-4,360 Closed
0 $0
Q2 2018

Aug 03, 2018
BUY
$9.16 - $13.48 $39,937 - $58,772
4,360 New
4,360 $49,000

Others Institutions Holding FATE

# of Institutions
175
Shares Held
115M
Call Options Held
53.7K
Put Options Held
9K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $220M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Sei Investments CO Portfolio

Follow Sei Investments CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email